This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Duggan, B. J. Articles by Zlotta, A. R. Search for Related Content PubMed PubMed Citation Articles by Duggan, B. J. Articles by Zlotta, A. R. Related Collections Clinical Research Clinical Research: Response Markers and Mechanisms

The Need to Embrace Molecular Profiling of Tumor Cells in Prostate and Bladder Cancer¹

Department of Urology, Belfast City Hospital, Belfast, Northern Ireland [B. J. D., J. J. M., S. R. J.]; Department of Pathology, Cancer Research Centre, Queen’s University Belfast [K. E. W., M. L., D. O., P. W. H.]; and Department of Urology, Hospital Erasme, Universite Libre de Bruxelles, Belgium [C. C. S., A. R. Z.]

Purpose: Current treatment strategies for urological cancer are still based on empirical formulae as opposed to treatment tailored for each cancer patient. To individualize treatment, the multiple molecular abnormalities within tumor cell populations needs to be mapped out. The aim of this article is to explain molecular profiling (MP) and its associated techniques so that the process is not purely seen as a research tool but as a future adjunctive measure in patient diagnosis and treatment.

Experimental Design: A Medline search of publications relating to MP of prostate and bladder cancer was carried out. A review article was written combining the relevant published literature along with the clinical and scientific experience of both centers.

Results: The advent of MP now provides a strategy by which these molecular abnormalities can be assessed. As well as being of diagnostic and prognostic use, these molecular profiles will identify putative molecular abnormalities within tumor cells that may be appropriate for therapeutic modulation.

Conclusions: In prostate and bladder cancer, mapping out the molecular abnormalities could be translated into a valuable tool to help solve difficult issues regarding patient management decisions.

This article has been cited by other articles:

				P. J. Wild, A. Herr, C. Wissmann, R. Stoehr, A. Rosenthal, D. Zaak, R. Simon, R. Knuechel, C. Pilarsky, and A. Hartmann Gene Expression Profiling of Progressive Papillary Noninvasive Carcinomas of the Urinary Bladder Clin. Cancer Res., June 15, 2005; 11(12): 4415 - 4429. [Abstract] [Full Text] [PDF]